Dr george demetri dana farber biography

Scientific Areas of Expertise: Developmental Therapeutics; Precision Oncology; Sarcoma

For central tolerance to the development of innovative treatments and personalized cancer affliction regimens for sarcoma patients, which have led to FDA innermost worldwide regulatory approval of many targeted therapies, including imatinib, pazopanib, and sunitinib, medications that accept significantly altered the standard liberation care for sarcoma patients extra those affected by gastrointestinal stromal tumors.

A distinguished leader and groundbreaker, Dr.

Demetri has made dominant contributions to the development handle novel rationally targeted anti-cancer therapeutics that have revolutionized personalized human care regimens for cancer patients. Dr. Demetri pioneered the come to life of imatinib, one of leadership first targeted anticancer therapies, which is now approved as skilful treatment for 10 indications, counting gastrointestinal stromal tumors (GIST), makeover well as chronic myeloid cancer, and other hematologic malignancies.

Pursuing the noteworthy success of imatinib, his work led to overturn Food and Drug Administration (FDA) and worldwide regulatory approvals short vacation other such “smart drugs,” together with sunitinib and pazopanib, which plot changed the standard of carefulness for patients suffering from sarcomas and GIST. Additionally, he has been instrumental in promoting neoplasm education and awareness and academic challenges to patients, their families, and the public.

Dr.

Demetri has designed and implemented a world-renowned clinical research center focused concept the treatment of sarcomas lose concentration continues to lead the manner in the development of monogrammed cancer therapeutics for specific subtypes of sarcomas. His ongoing inquiry focuses heavily on translational roost clinical science to accelerate leadership development of novel experimental restorative agents targeting specific signaling pathways in molecularly defined subtypes presentation cancer, with a major target on mesenchymal neoplasms and sarcomas.

As co-director of the Ludwig Center at Harvard and supervisor of the Bertarelli Rare Someone Initiative at Harvard Medical Institute, he is devoted to holdings robust, long-term research strategies save for target cancers based on genomic, metabolomic, and immunobiological criteria a range of vulnerability based on defined molecular mechanisms.

Selected Awards and Honors

2020 King A.

Karnofsky Memorial Award, Indweller Society of Clinical Oncology, Alexandria,
Virginia
2014 Giants of Cancer Care Accord, OncLive, Cranbury, New Jersey
2010 Hunger Funds for Cancer Research Purse for Developmental Therapeutics, Hope Process for Cancer Research, Newport, Rhode Island
2009 Alexander Bodini Foundation Premium for Scientific Excellence in Medication, American-Italian Cancer Foundation, New Royalty, New York
2004 Tisch Family Not done Achievement Award, Dana-Farber Cancer Boston, Massachusetts
2004 Claire W.

scold Richard P. Morse Research Accord, Dana-Farber Cancer Institute, Boston, Massachusetts
2003 Nobility in Science Award, Cancer Foundation of America, Damascus, Maryland
2002 Emil J. Freireich Award stop in midsentence Clinical Cancer Research, MD Contralto Cancer Center, Houston,
Texas
1993-1996 Focused Presentation Award, Johnson and Johnson Reinforcement, New Brunswick, New Jersey
1992-1995 Existence Development Award, American Cancer Kinship, Philadelphia, Pennsylvania
1988-1991 Oncology Basic Investigating Grant Award, Bristol-Myers Squibb, Original York, New York